A federal judge in Philadelphia is overseeing a rapidly expanding mass tort litigation that could affect millions of Americans who use popular GLP-1 weight loss and diabetes drugs. MDL 3163 — the standalone federal docket for Ozempic vision loss lawsuit claims — has grown from 21 cases at its December 2026 creation to 146 cases as of July 2026, with no signs of slowing. At the center of this litigation is a condition called non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and often permanent form of vision loss that plaintiffs allege was caused by semaglutide and tirzepatide drugs — and that drug manufacturers knew, or should have known, carried this risk long before warning patients or their doctors.
What Is MDL 3163 and Why Was It Created Separately?
On December 15, 2026, the U.S. Judicial Panel on Multidistrict Litigation (JPML) formally created IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, designated MDL 3163. The panel centralized all federal NAION-related GLP-1 lawsuits before Judge Karen Spencer Marston in the Eastern District of Pennsylvania — the same judge presiding over the parallel GI injury MDL 3094, which now carries more than 3,626 cases.
Critically, the JPML rejected Eli Lilly’s request to fold NAION claims into the existing gastrointestinal injury MDL. Instead, regulators created a standalone docket, recognizing that vision loss claims raise distinct scientific, medical, and legal questions from gastroparesis and bowel obstruction claims. This separation matters: it signals that the court views NAION as a serious, independently cognizable injury category deserving its own litigation track.
Defendants named in MDL 3163 include Novo Nordisk (makers of Ozempic, Wegovy, and Rybelsus, all semaglutide-based) and Eli Lilly (makers of Mounjaro and Zepbound, which contain tirzepatide, a dual GIP/GLP-1 receptor agonist). If you have used any of these medications and experienced sudden vision changes, your claim may fall within this docket. You can use our medical malpractice calculator to begin estimating the potential value of a defective drug injury claim.
Beyond the federal MDL, over 100 additional GLP-1 NAION cases have been filed in New Jersey state court, centralized in Bergen County under MCL No. 644, creating a parallel state-level litigation track that further underscores the breadth of this emerging mass tort.
The Science Behind the Ozempic Vision Loss Lawsuit
What Is NAION?
Non-arteritic anterior ischemic optic neuropathy — NAION — is sometimes described as an “eye stroke.” It occurs when blood flow to the optic nerve is suddenly interrupted, causing rapid, painless, and in most cases irreversible vision loss in one or both eyes. Unlike many medical conditions, NAION typically strikes without warning and offers no reliable treatment to restore lost sight. For patients who were using Ozempic or Wegovy for weight management or blood sugar control, the onset of this condition has been devastating and life-altering.
What the Research Shows
The causal science linking GLP-1 receptor agonists to NAION has developed rapidly. A landmark July 2026 study published in JAMA Ophthalmology by researchers at Harvard and Mass Eye and Ear found a significantly elevated NAION risk among semaglutide users compared to non-users. A separate study published in JAMA Network Open, drawing on Veterans Affairs patient data, found that GLP-1 drug users faced a higher three-year NAION risk than patients using older SGLT2 diabetes medications — a direct head-to-head comparison that strengthens the causal inference. A third study published in the British Journal of Ophthalmology found that Wegovy users may face nearly five times the risk of ischemic optic neuropathy including NAION compared to control populations.
These converging lines of research from multiple independent research institutions form the scientific backbone of the Ozempic vision loss lawsuit claims now consolidated in MDL 3163.
MDL 3163 Case Growth and Docket Timeline
The pace at which new plaintiffs are joining MDL 3163 is one of the clearest indicators that this litigation is accelerating. The table below tracks docket growth from the MDL’s creation through July 2026:
| Date | Number of Cases | Net Change |
|---|---|---|
| December 15, 2026 (MDL Created) | 21 | — |
| March 2, 2026 | 54 | +33 |
| April 1, 2026 | 73 | +19 |
| May 2026 | 86 | +13 |
| June 1, 2026 | 110 | +24 |
| July 2026 | 146 | +36 |
The July 2026 addition of 36 new cases in a single month represents the largest single-month increase since the MDL was created and suggests that plaintiff recruitment is gaining momentum as public awareness of the Ozempic vision loss lawsuit grows. For context, the parallel GI injury MDL 3094 now has over 3,600 cases — meaning the NAION docket, while smaller, is on a steep upward trajectory. Approximately 12% of Americans have been prescribed Ozempic or a similar GLP-1 drug, representing an enormous potential plaintiff population.
June 2, 2026 Science Day: A Pivotal Moment for the Litigation
On June 2, 2026, Judge Marston convened a formal Science Day under Case Management Order No. 6 — a non-adversarial proceeding in which both plaintiffs and defendants were each given 2.5 hours to present the scientific evidence on the causal relationship between GLP-1 drugs and NAION. Science Days are a recognized tool in complex MDL proceedings, allowing a judge to build deep technical literacy before ruling on dispositive motions or Daubert challenges to expert testimony.
The fact that Judge Marston ordered Science Day at this stage — with the docket still below 150 cases — indicates she is treating the causal science as a threshold issue requiring early resolution. Seeger Weiss partner Parvin Aminolroaya, appointed Co-Lead Counsel in MDL 3163, was among the plaintiffs’ representatives who participated in shaping the proceeding. A follow-up status conference was held on June 23, 2026 to assess case progress and next steps, including the likely schedule for expert discovery and bellwether selection. For plaintiffs considering the value of their claims, our personal injury settlement calculator can provide a general baseline — though mass tort settlements are ultimately driven by MDL-specific factors including docket size and bellwether outcomes.
The Regulatory Gap at the Heart of Every Ozempic Vision Loss Lawsuit
What the FDA Has — and Has Not — Done
Perhaps the most legally significant fact in this entire litigation is this: as of July 2026, the U.S. Food and Drug Administration has not required Novo Nordisk or Eli Lilly to add a NAION warning to U.S. drug labels for Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound. This regulatory inaction exists despite mounting scientific evidence and despite parallel regulatory action by agencies in other major markets.
In June 2025, the European Medicines Agency (EMA) added NAION as a “very rare” side effect and required label updates for Ozempic, Wegovy, and Rybelsus across EU member states. In February 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published a direct safety advisory warning patients using semaglutide to seek immediate medical attention if they experience sudden vision changes. You can review the FDA’s labeling regulations under 21 CFR to understand the legal standards that govern when manufacturers must update drug warnings in the United States.
Why This Matters for Failure-to-Warn Claims
Under U.S. product liability law, a drug manufacturer has an independent duty to warn patients and prescribing physicians of known or reasonably knowable risks — a duty that exists separately from FDA label approval. Because no U.S. NAION warning has been issued, plaintiffs in every Ozempic vision loss lawsuit can argue that Novo Nordisk and Eli Lilly failed to update their warnings even as European regulators acted, even as peer-reviewed studies accumulated, and even as patients continued losing their sight. Importantly, because no label warning exists, the lawsuits properly target the manufacturers directly — not the prescribing physicians who had no labeled risk to communicate. This distinction protects both patients and their doctors while placing accountability squarely on the companies that controlled the warning language.
What GLP-1 Patients Who Suffered Sudden Vision Loss Should Do Right Now
If you were taking Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound and experienced sudden, painless vision loss in one or both eyes, time is working against you on multiple fronts. Statutes of limitations vary by state, and as MDL 3163 advances toward bellwether trials, early-filed cases typically receive preferential scheduling in the bellwether selection process. Here is what you should do immediately:
- Seek or confirm a formal NAION diagnosis from an ophthalmologist or neuro-ophthalmologist. A medical record linking your vision loss to optic nerve ischemia is essential documentation for any Ozempic vision loss lawsuit.
- Preserve all prescription records — pharmacy fill histories, refill dates, dosage levels, and prescribing physician notes — to establish the timeline of your GLP-1 drug use relative to vision loss onset.
- Document your vision loss thoroughly, including visual field test results, OCT imaging of the optic nerve, and any records of emergency or urgent care visits at the time of onset.
- Do not assume your doctor warned you adequately — because no U.S. label warning exists, your prescriber almost certainly could not have warned you about NAION risk at the time of prescribing.
- Contact a mass tort attorney promptly to evaluate whether your claim qualifies for filing in MDL 3163 or the parallel NJ state MCL No. 644 docket before applicable statutes of limitations expire in your state.
Frequently Asked Questions About the Ozempic Vision Loss Lawsuit
What drugs are covered by the GLP-1 NAION MDL 3163?
MDL 3163 covers NAION vision loss claims against Novo Nordisk’s semaglutide drugs — Ozempic, Wegovy, and Rybelsus — and Eli Lilly’s tirzepatide drugs, Mounjaro and Zepbound. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both GIP and GLP-1 receptors and is considered a closely related drug class. Any patient who used one of these five medications and subsequently developed NAION-type vision loss may have a viable claim under the Ozempic vision loss lawsuit MDL framework.
Is MDL 3163 the same as the Ozempic GI injury lawsuit?
No. MDL 3163 is an entirely separate docket from MDL 3094, which covers gastrointestinal injury claims such as gastroparesis, stomach paralysis, and bowel obstruction. When the JPML created MDL 3163 in December 2026, it specifically rejected Eli Lilly’s request to consolidate NAION cases with the GI injury MDL. While both MDLs are before Judge Karen Spencer Marston in the Eastern District of Pennsylvania, they have separate case management orders, separate lead counsel, separate science tracks, and separate timelines. A patient can potentially have claims in both MDLs if they suffered both GI injuries and NAION vision loss from GLP-1 drug use.
Why hasn’t the FDA added a NAION warning to Ozempic or Wegovy labels?
As of July 2026, the FDA has not required Novo Nordisk or Eli Lilly to add a NAION warning to any U.S. drug label — despite the European Medicines Agency adding NAION as a “very rare” side effect in June 2025 and the UK MHRA publishing a safety advisory in February 2026. The FDA operates under its own regulatory review standards and timelines, and the agency has not publicly explained the delay relative to European action. Plaintiffs in the Ozempic vision loss lawsuit argue that regardless of FDA action, manufacturers had an independent legal duty to warn once the scientific evidence of risk became apparent — a duty they allegedly breached.
What does the Harvard study actually prove about Ozempic and vision loss?
The July 2026 Harvard and Mass Eye and Ear study, published in JAMA Ophthalmology, found a statistically significant elevated risk of NAION among patients using semaglutide compared to those not using the drug. A separate VA study published in JAMA Network Open compared GLP-1 users directly against patients taking older SGLT2 diabetes medications and found GLP-1 users had higher three-year NAION risk. A third study in the British Journal of Ophthalmology found Wegovy users may face nearly five times the risk of ischemic optic neuropathy. These studies do not individually prove causation in any specific plaintiff’s case, but together they form the scientific foundation — the “general causation” evidence — that plaintiffs must establish at Science Day and in eventual Daubert hearings before individual cases can proceed to trial.
How long do I have to file an Ozempic vision loss lawsuit?
Statutes of limitations for product liability claims vary significantly by state — typically ranging from two to four years from the date of injury or discovery of the injury. In many states, the clock starts running from when you first experienced vision loss or when you first reasonably should have connected your vision loss to your GLP-1 medication. Because MDL 3163 is still in its early pretrial phase with 146 cases as of July 2026, the window to join the litigation with a well-positioned early-filed claim remains open — but it will not remain open indefinitely. Consulting with a mass tort attorney as soon as possible after diagnosis is strongly advised to protect your right to file an Ozempic vision loss lawsuit before your state’s deadline expires.
This article is provided for informational purposes only and does not constitute legal advice or create an attorney-client relationship; consult a licensed attorney in your jurisdiction regarding your specific legal situation.
Related reading: Personal Injury Settlement Guide 2026-07-11
Related reading: $100 Million Verdict: Who Has Legal Standing To Sue For Wrongful Death — And Who Gets Shut Out
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.